Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

REGENERON PHARMACEUTICALS ($REGN) Releases Q1 2026 Earnings - Quiver Quantitative

AI-generated analysis

πŸ“Š Regeneron Pharmaceuticals reported Q1 2026 earnings of $9.47 per share, exceeding analyst estimates of $9.07 by $0.40.

πŸ’° Revenue reached $3.6 billion, surpassing expectations of $3.55 billion by approximately $53 million.

πŸ“‰ Insider trading activity shows 44 sales and zero purchases in the last six months as insiders sold on the open market.

🏦 Institutional investors split their positions with 680 adding shares while 590 decreased holdings during the most recent quarter.

πŸ’Ή Members of Congress made two net purchase transactions over the past six months, resulting in no sales.

🀝 Wall Street sentiment is bullish with five firms issuing buy ratings and zero sell ratings on the stock recently.

🎯 A total of 19 analysts have provided price targets for the stock, establishing a median target price of $865.00.

⚠️ Readers are reminded that the report includes disclaimers regarding financial advice and potential ticker-mapping inaccuracies.

Bullish Signals
  • REGENERON PHARMACEUTICALS reported earnings of $9.47 per share for Q1 2026, which beats analyst estimates of $9.07 by $0.40.
  • Revenue of $3.6 billion came in ahead of estimates at $3.55 billion, exceeding expectations by approximately $53 million.
  • Wall Street analysts have issued a strong consensus with five firms issuing buy ratings and zero sell ratings for the stock.
  • Multiple analysts have provided bullish price targets, with 19 analysts setting median target prices at $865.0 over the last six months.
  • Members of Congress have shown net buying interest in REGENERON PHARMACEUTICALS, recording two purchases with no sales in the past six months.
Risk Factors
  • Insiders have sold $REGN stock 44 times in the past 6 months with zero purchases, indicating potential lack of confidence from company insiders.
  • Institutional investors showed mixed sentiment with 590 reducing their positions compared to 680 adding shares, suggesting some hedge fund caution.
  • The median analyst price target of $865.0 provides a specific downside reference point relative to current market conditions.
Full Analysis
Regeneron Pharmaceuticals ($REGN) announced its Q1 2026 earnings results on Wednesday, April 29th, delivering figures that surpassed Wall Street expectations. The biotechnology and pharmaceutical company reported a quarterly earnings per share of $9.47, exceeding analyst estimates of $9.07 by $0.40. Revenue for the quarter totaled $3,605.4 million, which represented an overperformance against estimates of $3,552.4 million by approximately $53 million. These results highlight continued strong financial performance despite the broader market dynamics in late 2026. Insider trading activity has been predominantly sell-side during the six-month period leading up to the earnings release. Company insiders have executed 44 trades on the open market, with all instances being sales and zero purchases recorded. This contrasts with institutional investor behavior, where net additions were positive; specifically, 680 institutional investors increased their holdings of $REGN stock while 590 decreased theirs in the most recent quarter. Additionally, members of Congress have shown a bullish stance recently, executing two trades in the past six months consisting entirely of purchases with no sales. Wall Street sentiment toward Regeneron remains cautiously optimistic based on analyst ratings and price targets. Five firms issued buy ratings on the stock in the last several months, while no sell ratings were recorded. A total of 19 analysts have provided price targets over the previous six months, resulting in a median target of $865.00 per share. These figures suggest sustained interest from professional investors, though the heavy insider selling warrants monitoring for potential short-term supply effects.